Chemical Properties of Antimicrobials and Their Uniqueness

Chapter
First Online:

Abstract

Antibacterial drug discovery has benefitted from the availability of a large number of genome sequences for target selection and new assay formats for inhibitor identification. Until recently, however, little consideration was given to the chemical properties of the compounds screened against these targets. Most screening campaigns have been performed with compound libraries that are ill suited for antibacterial lead optimization. Antibacterial agents occupy a different region of physicochemical property space than compounds from other drug classes. In particular, the structural complexity of antimicrobials is generally greater, with an increased density of polar functionality, a larger number of chiral centers, and a higher molecular weight. These unusual chemical properties are a function of the cellular penetration requirements and the pharmcodynamic behavior of antibacterial drugs, among other factors. The optimal compound library for screening against antibacterial targets would consist of natural products and synthetic chemicals designed to inhabit a similar region of chemical property space as natural products.

Keywords

Antibacterial Agent Hydrogen Bond Donor Antibacterial Drug Rotatable Bond Compound Library 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviations

ClogP

Calculated logarithm of the partition coefficient

CMC

Comprehensive Medicinal Chemistry

DOS

Diversity-oriented synthesis

LogP

Logarithm of the partition coefficient

MRSA

Methicillin-resistant Staphylococcus aureus

TPSA

Total polar surface area

This is a preview of subscription content, log in to check access.

References

  1. 1.
    Baltz RH (2007) Antimicrobials from actinomycetes: back to the future. Microbe 2:125–131Google Scholar
  2. 2.
    Banskota AH, McAlpine JB, Sorensen D et al (2006) Genomic analyses lead to novel secondary metabolites. Part 3 ECO-0501, a novel antibacterial of a new class. J Antibiot 59: 533–542PubMedCrossRefGoogle Scholar
  3. 3.
    Bell IM, Gallicchio SN, Abrams M et al (2002) 3-Aminopyrrolidinones farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency. J Med Chem 45:2388–2409PubMedCrossRefGoogle Scholar
  4. 4.
    Bosnar M, Kelnerić Z, Munić V, Eraković V et al (2005) Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. Antimicrob Agents Chemother 49:2372–2377PubMedCrossRefGoogle Scholar
  5. 5.
    Burke MD, Berge EM, Schreiber SL (2003) Generating diverse skeletons of small molecules combinatorially. Science 302:613–618PubMedCrossRefGoogle Scholar
  6. 6.
    Butler MS, Buss AD (2006) Natural products – The future scaffolds for novel antibiotics? Biochem Pharmacol 67:2141–2153Google Scholar
  7. 7.
    Chakrabarti K, Banerjee S (1977) Mechanism of intestinal absorption of chloramphenicol. Indian J Exp Biol 15:302–303PubMedGoogle Scholar
  8. 8.
    Clark DE (1999) Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. J Pharm Sci 88:807–814PubMedCrossRefGoogle Scholar
  9. 9.
    Clark DE (1999) Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. J Pharm Sci 88:815–821PubMedCrossRefGoogle Scholar
  10. 10.
    Coates ARM, Hu Y (2007) Novel approaches to developing antibiotics for bacterial infections. Brit J Pharmacol 152:1147–1154CrossRefGoogle Scholar
  11. 11.
    Constantino L, Barlocco D (2006) Privileged structures as leads in medicinal chemistry. Curr Med Chem 13:65–85CrossRefGoogle Scholar
  12. 12.
    Cormet E, Huneau J-F, Bouras M et al (1997) Evidence for a passive diffusion mechanism for sparfloxacin uptake at the brush-border membrane of the human intestinal cell-line Caco-2. J Pharm Sci 86:33–36PubMedCrossRefGoogle Scholar
  13. 13.
    Daniel R (2004) The soil metagenome – a rich source for the discovery of novel natural products. Curr Opin Biotechnol 15:199–204PubMedCrossRefGoogle Scholar
  14. 14.
    Egan WJ, Merz KM Jr, Baldwin JJ (2000) Prediction of drug absorption using multivariate statistics. J Med Chem 43:3867–3877PubMedCrossRefGoogle Scholar
  15. 15.
    Galloway WRJD, Bender A, Welch M et al (2009) The discovery of antibacterial agents using diversity-oriented synthesis. Chem Commun 18:2446–2462CrossRefGoogle Scholar
  16. 16.
    Ghose AK, Viswanadhan VN, Wendoloski JJ (1998) Prediction of hydrophobic (lipophilic) properties of small organic molecules using fragmental methods: an analysis of ALOGP and CLOGP methods. J Phys Chem A 102:3762–3772CrossRefGoogle Scholar
  17. 17.
    Grabowski K, Schneider G (2007) Properties and architecture of drugs and natural products revisited. Curr Chem Biol 1:115–127CrossRefGoogle Scholar
  18. 18.
    Gualtieri M, Banéres-Roquet F, Villain-Guillot P et al (2009) The antibiotics in the chemical space. Curr Med Chem 16:390–393PubMedCrossRefGoogle Scholar
  19. 19.
    He H, Williamson RT, Shen B et al (2002) Mannopeptimycins, novel antibacterial glycopeptides from Streptomyces hygroscopicus, LL-AC98. J Am Chem Soc 124:9729–9736PubMedCrossRefGoogle Scholar
  20. 20.
    Holtzel A, Schmid DG, Nicholson GJ et al (2002) Biosynthetic capacities of actinomycetes Arylomycins A and B, new biaryl-bridged lipopeptide antibiotics produced by Streptomyces sp. Tu 6075. 1. Toxonomy, fermentation, isolation and biological activities. J Antibiot 55:565–570PubMedGoogle Scholar
  21. 21.
    Hornung A, Bertazzo BO, Piraee M et al (2007) A genomic screening approach to the structure-guided identification of drug candidates from natural sources. Chembiochem 8:757–766PubMedCrossRefGoogle Scholar
  22. 22.
    Leeds JA, Schmitt EK, Krastel P (2006) Recent developments in antibacterial drug discovery: microbe-derived natural products – from collection to the clinic. Expert Opin Investig Drugs 15:211–226PubMedCrossRefGoogle Scholar
  23. 23.
    Leeson PD, Davis AM (2004) Time-related differences in the physical property profiles of oral drugs. J Med Chem 47:6338–6348PubMedCrossRefGoogle Scholar
  24. 24.
    Leo A, Jow PYC, Silipo C, Hansch C (1975) Calculation of hydrophobic constant (logP) from π and f constants. J Med Chem 18:865–868PubMedCrossRefGoogle Scholar
  25. 25.
    Lipinski CA, Lombardo F, Dominy BW et al (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3–25CrossRefGoogle Scholar
  26. 26.
    Martin YC (2005) A bioavilability score. J Med Chem 48:3164–3170PubMedCrossRefGoogle Scholar
  27. 27.
    Martinez A, Hopke J, MacNeil AI, Osburne MS (2005) Accessing the genomes of uncultivated microbes for novel natural products. In: Xhang L, Demain AL (eds) Natural products: drug discovery and therapeutic medicine. Humana Press, TotowaGoogle Scholar
  28. 28.
    Marquis RW, Ru Y, LoCastro SM et al (2001) Azepanone-based inhibitors of human and rat cathepsin K. J Med Chem 44:1380–1395PubMedCrossRefGoogle Scholar
  29. 29.
    Meshali MM, Attia IE (1978) Transport mechanism of some naturally occurring tetracyclines across everted rat gut. Can J Pharm Sci 13:42–45Google Scholar
  30. 30.
    Miller JR, Dunham S, Mochalkin I et al (2009) A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore. Proc Natl Acad Sci USA 106:1737–1742PubMedCrossRefGoogle Scholar
  31. 31.
    Mochalkin I, Miller JR, Narasimhan L (2009) Discovery of antibacterial biotin carboxylase inhibitors by virtual screening and fragment-based approaches. ACS Chem Biol 4:473–483PubMedCrossRefGoogle Scholar
  32. 32.
    Nicolaou KC, Pfefferkorn JA, Roecker AJ et al (2000) Natural product-like combinatorial libraries based on privileged structures. 1. General principles and solid-phase synthesis of benzopyrans. J Am Chem Soc 122:9939–9953CrossRefGoogle Scholar
  33. 33.
    Nicolaou KC, Roecker AJ, Barluenga S et al (2001) Discovery of novel antibacterial agents active against methicillin-resistant Staphylococcus aureus from combinatorial benzopyran libraries. Chembiochem 2:460–465PubMedCrossRefGoogle Scholar
  34. 34.
    Nielsen CU, Brodin B, Jorgensen FS et al (2002) Human peptide transporters: therapeutic applications. Expert Opin Ther Pat 12:1329–1350CrossRefGoogle Scholar
  35. 35.
    Nören-Müller A, Reis-Correa I Jr, Prinz H et al (2006) Discovery of protein phosphatase inhibitor classes by biology-oriented synthesis. Proc Natl Acad Sci USA 103:10606–10611PubMedCrossRefGoogle Scholar
  36. 36.
    Nören-Müller A, Wilk W, Saxena K et al (2008) Discovery of a new class of inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B by biology-oriented synthesis. Angew Chem Int Ed Engl 47:5973–5977PubMedGoogle Scholar
  37. 37.
    Nikaido H, Thanassi DG (1993) Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples. Antimicrob Agents Chemother 37:1393–1399PubMedGoogle Scholar
  38. 38.
    Nikaido H (1996) Multidrug efflux pumps of Gram-negative bacteria. J Bacteriol 178:5853–5859PubMedGoogle Scholar
  39. 39.
    Nikaido H (2003) Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev 67:593–656PubMedCrossRefGoogle Scholar
  40. 40.
    O’Shea R, Mozer HE (2008) Physicochemical properties of antibacterial compounds: implications for drug discovery. J Med Chem 51:2871–2878PubMedCrossRefGoogle Scholar
  41. 41.
    Overbye KM, Barrett JF (2005) Antibiotics: where did we go wrong? Drug Discov Today 10:45–52PubMedCrossRefGoogle Scholar
  42. 42.
    Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL (2007) Drugs for bad bugs: confronting the challenges of antibacterial drug discovery. Nat Rev Drug Discov 6:29–40PubMedCrossRefGoogle Scholar
  43. 43.
    Projan SJ (2002) New (and not so new) antibacterial targets – from where and when will the novel drugs come? Curr Opin Pharmacol 2:513–522PubMedCrossRefGoogle Scholar
  44. 44.
    Schnarr NA, Khosla C (2007) Combinatorial biosynthesis of polyketides and nonribosomal peptides. In: Schreiber SL, Kapoor TM, Wess G (eds) Chemical biology. From small molecules to system biology and drug design. Wiley-VCH Verlag GmbH, Co. KGaA, WeinheimGoogle Scholar
  45. 45.
    Schneider T, Gries K, Josten M et al (2009) The lipopeptide antibiotic friulimicin B inhibits cell wall biosynthesis through complex formation with bactoprenol phosphate. Antimicrob Agents Chemother 53:1610–1618PubMedCrossRefGoogle Scholar
  46. 46.
    Silver LL (2008) Are natural products still the best source for antibacterial discovery? The bacterial entry factor. Expert Opin Drug Dis 3:487–500CrossRefGoogle Scholar
  47. 47.
    Tan DS (2004) Current progress in natural product-like libraries for discovery screening. Comb Chem High Throughput Screen 7:631–643PubMedGoogle Scholar
  48. 48.
    Thomas GL, Spandl RJ, Glansdorp FG et al (2008) Anti-MRSA agent discovery using diversity-oriented synthesis. Angew Chem Int Ed Engl 47:2808–2812PubMedCrossRefGoogle Scholar
  49. 49.
    Veber DF, Johnson SR, Cheng H-Y et al (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45:2615–2623PubMedCrossRefGoogle Scholar
  50. 50.
    Vieth H, Siegel MG, Higgs RE et al (2004) Characteristic physical properties and structural fragments of marketed oral drugs. J Med Chem 47:224–232PubMedCrossRefGoogle Scholar
  51. 51.
    von Nussbaum F, Brands M, Hinzen B et al (2006) Antibacterial natural products in medicinal chemistry – exodus or revival? Angew Chem Int Ed Engl 45:5072–5129CrossRefGoogle Scholar
  52. 52.
    Walsh CT, Fischbach MA (2009) Repurposing libraries of eukaryotic protein kinase inhibitors for antibiotic discovery. Proc Natl Acad Sci USA 106:1689–1690PubMedCrossRefGoogle Scholar
  53. 53.
    Watve MG, Tickoo R, Jog MM, Bhole BD (2001) How many antibiotics are produced by the genus Streptomyces? Arch Microbiol 176:386–390PubMedCrossRefGoogle Scholar
  54. 54.
    Wilk W, Nören-Müller A, Kaiser M, Waldmann H (2009) Biology-oriented combined solid- and solution-phase synthesis of a macroline-like compound collection. Chem Eur J 15:11976–11984PubMedCrossRefGoogle Scholar
  55. 55.
    Wyatt EE, Galloway WRJD, Thomas GL, et al (2008) Identification of an anti-MRSA dihydrofolate reductase inhibitor from a diversity-oriented synthesis. Chem Commun 2010:4962–4964Google Scholar
  56. 56.
    Yamaguchi H, Ikuko S, Saito H et al (2001) Transport characteristics of grepafloxacin and levofloxacin in the human intestinal cell line Caco-2. Eur J Pharmacol 431:297–303PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Johnson & Johnson Pharmaceutical Research & DevelopmentSpring HouseUSA

Personalised recommendations